MENU

Company news

New indications of IMM01 project of ImmuneOnco obtained NMPA clinical trial research license

Date:2021-01-20 Views:688

On January 20, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (MM, AML and MDS) and obtaining NMPA clinical trial research license. This is another milestone of ImmuneOnco's further research and development of CD47 target drugs, and further establishes ImmuneOnco's leading echelon position in the research and development of CD47 target drugs.



"We are very glad to see that our IMM01 project has obtained the NMPA clinical trial research license to expand new indications. The phase I clinical trial of IMM01 project for lymphoma (HL & NHL) is coming to an end, and has obtained exciting clinical manifestations! We think that this is due to the difference design of IMM01 itself. IMM01 does not bind to human red blood cells at all. It avoids "antigenic sink" and does not appear ADA. It has small molecule (half of antibody). It has good tissue permeability and bioavailability. Therefore, we believe that IMM01 will have great advantages in clinical development. " Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, is full of confidence in the clinical trial of IMM01. "We hope to further expand the research on new indications and combination drugs of IMM01 project in the future, so as to benefit more subjects. We will accelerate the clinical trial research of IMM01 and accelerate the listing of IMM01, so as to benefit cancer patients as soon as possible. ".


About IMM01

IMM01 project for injection is a new generation of immune checkpoint inhibitor with independent intellectual property rights, which is developed based on the "mAb-Trap" technology platform of ImmuneOnco. Targeting at the immune regulatory target CD47, IMM01 project can activate the phagocytosis of macrophages on tumor cells, and present the phagocytized tumor antigen to T cells, so as to play a strong role in tumor immunotherapy. IMM01 project perfectly solves the core pain point of CD47 target drug research and development, and has obtained invention patents in China, Japan and the United States.


About ImmuneOnco

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TANKTM cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.

Contact us

Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China

               Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China

Tel. + 86 21 5835 6573

website: www.immuneonco.com